Terbinafine is a synthetic antifungal agent which has recently been found to be highly effective against Pneumocystis carinii. This study evaluated the efficacy of terbinafine on rat P. carinii antigenic profile and the immune response by Western blot analysis, in comparison with atovaquone and co-trimoxazole in rats with pneumocystosis. Terbinafine was shown to target two specific major antigens, particularly those of 116 and 35-40 kDa. Antibodies reactive against these moieties were found in all rats treated with atovaquone and co-trimoxazole, but not in those treated with terbinafine. These surface antigen modifications could be related to disease severity and could provide additional information for monitoring the efficacy of this treatment.
Introduction
In recent years marked molecular and biological affinities have suggested that Pneumocystis carinii should be classified as a fungus. Antifungal agents could thus represent potential therapeutic and prophylactic drugs against this organism.
1 A number of these compounds with different mechanisms of action have been evaluated extensively, both in vitro and in vivo, and seem to be promising. To date the most important agents are two classes of (1,3)--Dglucan synthase inhibitors, the echinocandins and papulacandins. 2 Because of the high incidence of side effects associated with standard anti-Pneumocystis regimens, research continues to identify other antifungal agents with anti-P. carinii potential, though the sensitivity of the organism to these compounds alone or in combination is not completely established. Recently, an antifungal and antiprotozoal compound, the allylamine-derived terbinafine, has been shown to be very effective in vitro against P. carinii and in the treatment of rat P. carinii pneumonia (PCP). This was first discovered by Contini et al., 3 and later confirmed by other investigators. 4 Although various mechanisms of action of terbinafine have been suggested, it is not known how P. carinii is cleared from rat lung after treatment. In this paper we examined the anti-P. carinii efficacy of terbinafine by investigating the antigenic pattern of P. carinii isolated from the bronchoalveolar lavage fluid (BALF) of immunosuppressed rats and by assessing the specific serological response by Western blotting in comparison with two reference anti-P. carinii drugs, atovaquone and co-trimoxazole.
Materials and methods

Rat immunosuppression and drug administration
PCP was induced by immunosuppressing 180-250 g male Sprague-Dawley rats (Charles River, Como, Italy) with 25 mg/L of subcutaneous methylprednisolone acetate (Solu-medrol; Upjohn, Milan, Italy) twice weekly for 10-12 weeks, and giving a low-protein diet to enhance the immunosuppression. Tetracycline was given by gavage to minimize other opportunistic infections. The percent survival was monitored. At intervals, randomly selected sample animals were killed and parasite burdens in the lungs were determined. The intensity of PCP was graded by scanning the impression smears and assigning an infection score of 0 (no infection evident) to 4 (heavy infection). 5, 6 PCP progressed consistently over time for each of the inoculation groups. By week 4, rats began to show signs of wasting, with marked weight loss; P. carinii infection
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Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia became intense with massive organism burden in 6-8 weeks. Rats were then randomly selected and divided into three groups of about 30 animals each of which received, by oral gavage, either co-trimoxazole (Sigma-Aldrich, Milan, Italy) (at a dose of 12.5 mg/kg/day of trimethoprim and 62.5 mg/kg/day of sulfamethoxazole) or atovaquone (Wellcome Italia, Rome, Italy) at 100 mg/kg/day, both found to have a significant dose-related effect in the treatment of pneumocystosis. Terbinafine (Sandoz, Basel, Switzerland) was given at 80 mg/kg/day, which has been shown to lead to significant clearance of P. carinii without significant histological changes. 6 After 4 weeks of drug administration, rats were killed and lungs were removed aseptically and weighed. Evaluation of drug efficacy was studied by comparing the P. carinii burden (mean infection score ± S.D.) and histological changes in the treatment groups with those in the controls in the same experiment. Control groups consisted of steroid-suppressed rats with PCP and uninfected and untreated rats. The in-vivo study was approved by the Institutional Animal Care and Use Committee.
Specimen collection and parasite load determination
BALF specimens were collected at the end of treatment at post-mortem. Broncheolar lavage of the right lung was performed with approximately 10 mL of 0.15 M NaCl, instilled in 3 mL fractions. Aliquots of BALF were subjected to microbiological tests, and any BALF samples containing bacteria or fungi that could potentially interfere with the detection of P. carinii were discarded. For quantification of P. carinii, BALF samples were centrifuged at 3500g for 10 min and the cellular pellet was resuspended in Hank's solution. Ten-microlitre drops of cell pellet were stained by methenamine silver stain. The number of cysts was scored on a semiquantitative scale (0 to 4 ) and the score was correlated with the cyst burden recorded in each rat lung (Spearman's rank correlation coefficient; statistical significance was at P 0.05). Infected sera were obtained by cardiac puncture when rats were bled. Sera were found to contain a high specific IgG antibody titre as measured by ELISA. 7 
Electrophoresis and Western blot analysis
After BALF protein determination (Bio-Rad Laboratories, Richmond, CA, USA), BALF pellets were solubilized by boiling for 10 min in 2% sodium dodecyl sulphate (SDS) lysis buffer containing 0.06 M Tris, 1% glycerol and 1.25% -mercaptoethanol. 8 Samples were centrifuged and then loaded at a concentration of 10 g of protein per lane (approximately 10 6 P. carinii cysts) to discontinuous SDS-polyacrylamide 4% stacking gel and 10% running gels at 10°C under 60 mA constant current using bromophenol blue as a marker. After completion of the run, gels containing separated antigens were either fixed in 40% methanol/10% acetic acid and stained with silver stain or were transferred to nitrocellulose in a Trans-blot cell (Bio-Rad) for 1 h at 60 V according to Towbin et al. 9 Nitrocellulose blots were probed overnight with infectionderived rat serum (1:200 dilution) and then washed in 0.5% Tween 20-Tris-buffered saline (TTBS). After incubation with alkaline phosphatase-conjugated goat anti-rat IgG (Dako, Copenhagen, Denmark) diluted 1:2000, strips were finally washed in TTBS and developed with the ECL chemiluminescence substrate (Amersham plc, Amersham, UK).
Results and discussion
As reported previously, mean survival rates of the untreated control rats were found to be shorter but not significantly different from the treated groups. 6 Also, 50% of the control rats exhibited a heavy P. carinii burden and severe alveolar involvement, with marked weight loss (P 0.01) after immunosuppression.The best inhibitory response was found in the terbinafine-and cotrimoxazole-treated groups in which PCP developed in a few animals with almost the same organism burden (mean infection score: 6 0.7 and 8 1.1, respectively, compared with 23 2.1 in the atovaquone-treated group), whereas histological lung changes were absent or minimal. 6 A significant relationship (P 0.001, r 0.472) was found when semiquantitative cyst counts between BALF and rat lungs were compared. This suggests that the P. carinii burden in BALF correctly reflects the organism burden in the lung. 10 The electrophoretic pattern of BALF preparations analysed by SDS-PAGE is presented in Figure 1 . Strong bands corresponding to major P. carinii antigens and ranging in size from 30 to 116 kDa were demonstrated in BALFs from control rats with PCP and, similarly, in atovaquone preparations. Neither the electrophoretic profile nor the antigen recognition pattern of BALFs from co-trimoxazole-treated rats differed substantially from that of atovaquone-treated animals (data not shown). In BALF preparations from terbinafine-treated animals, the 116 kDa protein was not stained but the bands at molecular masses of 35-40 kDa were almost absent. Bands at 97, 66 and 45 kDa were occasionally seen in normal BALF samples.
In preliminary experiments, sera collected before treatment have been shown to contain antibodies against some of the principal P. carinii proteins including those in the 35-40 kDa band. When the panel of each BALF preparation was probed with sera from P. carinii-infected rats, different patterns of immunoreactivity were detected by ECL Western blotting (Figure 2 ). Sera from control rats with PCP and from those treated with atovaquone recognized two or more antigens, particularly those of 116, 97, 66 and 35-40 kDa, but none of the terbinafine-treated rats had detectable antibodies against the 35-40 kDa protein, while Effect of terbinafine on P. carinii in rat a small number (two out of 30) showed a slight reactivity against the 116 kDa protein. Although no immunoreactivity towards the 116 or 35-40 kDa band was found by probing normal rat BALF with sera from infected rats or anti-P. carinii antiserum, the finding of faint bands on either silver staining preparations or blots is consistent with previous studies which confirm that animals as well as healthy humans have been exposed to P. carinii.
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The purpose of these experiments was to investigate whether Western blotting would provide meaningful data about the immune response to P. carinii antigens during drug administration. The 116 kDa protein is a component of the major surface glycoprotein (MSG), which participates in the attachment of P. carinii to alveolar epithelial cells. The immunoreactive moiety of molecular weight 35-40 kDa is the P. carinii antigen most commonly found in the respiratory tract in rat and in humans and most frequently recognized by the host; it can thus serve as an important marker of P. carinii infection.
Among the squalene-epoxydase inhibitors, terbinafine is the most potent agent against pathogenic fungi and is also active against protozoa. Although its mechanism of activity against P. carinii is not fully established, there is experimental evidence that terbinafine may target two important surface P. carinii antigens, the 116 and 35-40 kDa proteins. These changes may impair the organism's structural integrity and consequently either the mechanism of hostparasite interaction or the host immune response, thus providing additional information for monitoring the efficacy of this treatment. 
